Skip to main content
Year archive

Calliditas Therapeutics — 2019 filings

All 43 regulatory filings released by Calliditas Therapeutics (CALTX) in 2019, sourced directly from the official regulator.

43 Filings
2019 Period
2019 filings (43)
Filing Released Lang
Completion of recruitment of Part A of the NeflgArd pivotal Phase 3 clinical trial by year end
Regulatory Filings
2019-12-19 English
Rekryteringen till del A av den registreringsgrundande fas 3-studien NefIgArd slutförs vid årets slut
Regulatory Filings
2019-12-19 Swedish
China IND approval triggers $5 million milestone payment from Everest Medicines
Regulatory Filings
2019-12-17 English
IND-godkännande i Kina framkallar 5 miljoner dollar i milstolpsbetalning från Everest Medicines
Regulatory Filings
2019-12-17 Swedish
Krassimir Mitchev steps up as acting CMO
Board/Management Information
2019-11-14 English
Calliditas utser Krassimir Mitchev som tillförordnad CMO
Board/Management Information
2019-11-14 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report 9M 2019
2019-11-14 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report 9M 2019
2019-11-14 English
Calliditas Therapeutics valberedning utsedd inför årsstämma 2020
Board/Management Information
2019-11-11 Swedish
Calliditas Therapeutics’ nomination committee for the AGM 2020
AGM Information
2019-11-11 English
Positive interactions with EMA provide route to conditional marketing authorization of lead candidate Nefecon
Regulatory Filings
2019-10-01 English
Positiva interaktioner med EMA öppnar väg för villkorat godkännande av Calliditas ledande läkemedelskandidat Nefecon
Regulatory Filings
2019-10-01 Swedish
Positiv feedback från FDA har betydande påverkan på den pågående fas 3 studien NefIgArd
Regulatory Filings
2019-09-03 Swedish
Positive feedback from FDA significantly benefits ongoing NefIgArd pivotal Phase 3 study
Regulatory Filings
2019-09-03 English
Interim / Quarterly Report 2019
Interim / Quarterly Report H1 2019
2019-08-15 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report H1 2019
2019-08-15 English
Strategisk inlicensiering relaterad till autoimmun hepatit för den amerikanska marknaden
Regulatory Filings
2019-08-12 Swedish
Strategic in-licensing related to autoimmune hepatitis in the US market
Regulatory Filings
2019-08-12 English
Antal aktier och röster i Calliditas Therapeutics
Share Issue/Capital Change
2019-07-31 Swedish
Number of shares and votes in Calliditas Therapeutics
Declaration of Voting Results & Voting Rights Announcements
2019-07-31 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-07-05 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-07-04 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-07-03 English
Calliditas har beslutat om en riktad nyemission om 3,5 miljoner aktier och tillförs härigenom cirka 210 miljoner kronor
Capital/Financing Update
2019-07-03 Swedish
Calliditas has resolved on a directed share issue in the amount of 3.5 million shares, raising proceeds of approximately SEK 210 million
Capital/Financing Update
2019-07-03 English
Calliditas avser att genomföra en riktad nyemission
Capital/Financing Update
2019-07-02 Swedish
Calliditas considers a directed share issue
Capital/Financing Update
2019-07-02 English
Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore
Regulatory Filings
2019-06-10 English
Calliditas Therapeutics och Everest Medicines ingår avtal för att utveckla och kommersialisera Nefecon för IgA-nefropati i den kinesiska regionen och Singapore
Capital/Financing Update
2019-06-10 Swedish
Kommuniké från årsstämman i Calliditas Therapeutics AB (publ)
AGM Information
2019-05-08 Swedish
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
AGM Information
2019-05-08 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-05-08 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-05-08 English
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
AGM Information
2019-04-04 English
Annual Report 2018
Annual Report FY 2018
2019-04-04 Swedish
Annual Report 2018
Annual Report FY 2018
2019-04-04 English
Kallelse till årsstämma i Calliditas Therapeutics AB (publ)
AGM Information
2019-04-04 Swedish
Calliditas Therapeutics har beviljats särläkemedelsstatus av FDA för primär gallkolangit
Regulatory Filings
2019-02-12 Swedish
Calliditas Therapeutics granted orphan drug designation by the FDA for Primary biliary cholangitis
Regulatory Filings
2019-02-12 English
Interim / Quarterly Report 2018
Interim / Quarterly Report FY 2018
2019-02-07 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report FY 2018
2019-02-07 English
Calliditas Therapeutics har beviljats särläkemedelsstatus av FDA för autoimmun hepatit
Regulatory Filings
2019-02-05 Swedish
Calliditas Therapeutics granted orphan drug designation by the FDA for Autoimmune hepatitis
Regulatory Filings
2019-02-05 English